FGL1 and hepatocellular carcinoma: In a diethylnitrosamine-induced liver cancer model, Hashemi et al. discovered that FGL1 knockout increased HCC incidence by activating protein kinase B (Akt) and mammalian target of rapamycin (mTOR) pathways.